NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 258)
Posted On: 10/08/2019 4:35:35 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Provides R&D Program Update
Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today provided an update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria’s patented DehydraTECH(TM) technology. According to the update, most of the investigation and work within the first phase of the project underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) and Lexaria’s majority owned subsidiary Lexaria Nicotine LLC is either complete or significantly underway, with imminent commencement of one remaining aspect. Results have been positive to date and support successful completion of this first phase. “The program between Altria and Lexaria is progressing nicely and is enabling a clearer understanding of the potential of delivering nicotine through oral forms that avoid lung absorption,” Lexaria Bioscience and Lexaria Nicotine CEO Chris Bunka said in the news release. “Lexaria strongly believes that, given the choice, many of the world’s one billion smokers would elect to experience their nicotine in a manner that does not rely on either smoking or vaping, and Lexaria can help enable these alternatives.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today provided an update on the ongoing relationship and pursuit of innovation in oral, reduced risk nicotine consumer products using Lexaria’s patented DehydraTECH(TM) technology. According to the update, most of the investigation and work within the first phase of the project underway between Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE:MO) and Lexaria’s majority owned subsidiary Lexaria Nicotine LLC is either complete or significantly underway, with imminent commencement of one remaining aspect. Results have been positive to date and support successful completion of this first phase. “The program between Altria and Lexaria is progressing nicely and is enabling a clearer understanding of the potential of delivering nicotine through oral forms that avoid lung absorption,” Lexaria Bioscience and Lexaria Nicotine CEO Chris Bunka said in the news release. “Lexaria strongly believes that, given the choice, many of the world’s one billion smokers would elect to experience their nicotine in a manner that does not rely on either smoking or vaping, and Lexaria can help enable these alternatives.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼